Axelyf and Mote Therapeutics launch a licensed T-cell delivery package

Axelyf and Mote Therapeutics said they have formed a cross-license that gives third parties a single, off-the-shelf way to target nucleic acids to T cells for in vivo CAR-T development. The deal combines Axelyf’s lipid nanoparticle platform with Mote’s T-cell binder and is meant to simplify development and manufacturing.

Why it matters: - In vivo CAR-T developers often need to license delivery and targeting technologies separately, then prove the two work together. - The Axelyf-Mote package is meant to reduce that integration burden and speed up development of non-viral cell therapies. - The alliance could make targeted T-cell delivery easier to access for cell and gene therapy companies seeking scalability.

What happened: - Axelyf and Mote Therapeutics announced a cross-license agreement on September 9, 2026, in Boston. - The agreement combines Axelyf’s lipid nanoparticle technology with Mote’s T-cell targeting binder into a single license available to third parties. - Third-party partners will provide the nucleic acid payload.

The details: - Axelyf’s next-generation LNP platform has delivered up to 4x higher protein expression in head-to-head non-human primate studies than current clinical-stage benchmarks. - Mote’s bispecific antibody binder binds both the Axelyf LNP and CD8 on cytotoxic T cells. - Mote’s mobilize™ platform is designed to functionalize LNPs with cell-targeting specificity without covalent chemistry. - Earlier targeted LNP approaches attached targeting molecules to the particle surface through covalent chemistry, adding reaction and purification steps to manufacturing. - The companies said the shared solution gives developers a modular assembly process for simpler product generation and faster optimization at scale. - The financial terms of the agreement were not disclosed. - For more information, the companies listed Mote and Axelyf contact details and Axelyf’s website.

Between the lines: - The partnership is aimed at a core bottleneck in in vivo cell therapy: getting the right payload to the right cells without building a custom delivery stack from scratch. - By packaging targeting and delivery together, Axelyf and Mote are positioning the offering as a lower-friction option for partners entering the non-viral CAR-T market. - Axelyf’s lead candidate, AX-004, underscores that strategy by targeting solid tumors, where no approved CAR-T treatment currently exists.

What's next: - Axelyf and Mote said they will offer the combined delivery capability to partners in the cell and gene therapy space. - Developers using the platform would focus on engineering their nucleic acid therapy while the alliance handles delivery and T-cell targeting. - The companies did not disclose timing for partner programs or commercialization milestones.

The bottom line: - Axelyf and Mote are trying to turn a multi-step, custom licensing problem into a single, ready-to-use delivery solution for in vivo T-cell therapies.